The FDA has approved Blujepa for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae.

The FDA has approved GSK's gepotidacin (Blujepa), the first new antibiotic class for gonorrhea in over three decades, ...

US FDA approves GSK’s Blujepa as oral option for treatment of uncomplicated urogenital gonorrhoea: London, UK Saturday, December 13, 2025, 09:00 Hrs [IST] GSK plc announced that ...

A novel method converts industrial lignin waste into porous materials for effective removal of pollutants and bacteria from ...

Proteins need to fold into specific shapes to perform their functions in cells, but they occasionally misfold, which can ...

A research team from the Faculty of Engineering at The University of Hong Kong (HKU) has harnessed citywide genetic data and ...

A new Swedish innovation uses machine learning and laser scanning to identify contaminated water in just 20 minutes, reducing ...

The FDA has cleared the use of GSK’s Blujepa for the treatment of uncomplicated urogenital gonorrhea, unlocking the first new ...

Samsung Electronics Co., Ltd. today announced its upcoming showcase at CES 2026, which will be held Jan. 6-9 in Las Vegas, ...

Analyzing stochastic cell-to-cell variability can potentially reveal causal interactions in gene regulatory networks.

A low-dose antibiotic developed in Leiden may stop C. difficile infections more effectively by targeting the pathogen while preserving the gut microbiome. Researchers in Leiden have developed a new ...